Akebia Therapeutics, Inc. (AKBA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Akebia Therapeutics, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.30 $ — 15% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 74.9%
- Exp. sales growth 3Y > 5% -17.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -17.7%
- Net debt < 4x EBIT 1.3x
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% –
- ROCE > 15% 11.0%
- Expected return > 10% -1.4%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -6.9% failed
- More than 10% revenue growth is expected for the coming year -22.6% failed
- Share count grows by less than 3% a year 12.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 76.1% passed
- Gross margin at 40% or higher and without meaningful erosion 83.3% passed
- Goodwill from acquisitions does not grow faster than revenue 15.7% failed
- Net debt below twice EBITDA 1.5 x EBITDA passed
- Operating cash flow covers the profits of the last three years 131 m passed
- Return on capital at 15% or higher, or up versus two years ago 11.0% passed
- Insiders hold at least 10% or are net buyers 4.0% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 223.1% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.11 | -0.13 – -0.08 | 207 | -425.0% | 2 |
| 12/31/2027 | -0.19 | -0.20 – -0.18 | 160 | -81.0% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.03 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.10 | -3,335.10 | 47 | -17.30 | -49.00 | -5 | -5 |
| 2025: Q1 | 0.03 | – | 57 | 75.80 | 10.70 | -14 | -14 |
| 2025: Q2 | 0.00 | – | 63 | 43.10 | 0.40 | 22 | 22 |
| 2025: Q3 | 0.00 | – | 59 | 57.00 | 0.90 | 28 | 28 |
| 2025: Q4 | -0.05 | – | 58 | 23.90 | -21.20 | 31 | 31 |
| 2026: Q1 | -0.03 | -234.00 | 54 | -6.60 | -16.90 | -21 | -21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -136 | -136 | -3.60 | 58 | 68 | 300 |
| 2017 | 178 | -80 | -77 | -1.77 | -56 | 119 | 364 |
| 2018 | 208 | -178 | -172 | -1.47 | -97 | 636 | 997 |
| 2019 | 335 | -286 | -280 | -2.36 | -257 | 395 | 771 |
| 2020 | 295 | -376 | -350 | -2.53 | -110 | 248 | 644 |
| 2021 | 214 | -265 | -245 | -1.48 | -253 | 74 | 529 |
| 2022 | 292 | -81 | -94 | -0.52 | -73 | 5 | 356 |
| 2023 | 195 | -46 | -52 | -0.28 | -23 | -31 | 242 |
| 2024 | 160 | -50 | -69 | -0.33 | -41 | -49 | 221 |
| 2025 | 236 | 24 | -5 | -0.02 | 68 | 33 | 377 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Akebia Therapeutics, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Therapeutika für Patienten mit Nierenerkrankungen.
| Employees | 194 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | 245 First Street, 02142 Cambridge, United States |
| Phone | 617 871 2098 |
| Website | akebia.com |
| IPO Date | 20. Mar 2014 |
| ISIN | US00972D1054 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John P. Butler MBA | CEO, President & Director | 1964 |
| Erik John Ostrowski M.B.A. | Chief Business Officer, Senior VP, CFO & Treasurer | 1972 |
| Steven Keith Burke M.D. | Senior VP and Chief Research & Development Officer | 1961 |
| Nicholas Grund | Senior VP & Chief Commercial Officer | 1970 |
| Richard C. Malabre | Senior VP & Chief Accounting Officer | 1961 |
| Justin McCue Ph.D. | Senior VP & Chief Technology Officer | – |
| Mercedes Carrasco | Senior Director of Investor & Corporate Communications | – |
| Carolyn M. Rucci | Senior VP, Chief Legal Officer & Secretary | 1981 |
| Meredith Bowman | Senior VP & Chief People Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.